Clinical trials: Lipid Disorders
Generalized Lipodystrophy
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on…
- Trial name
- NCT04159415
- Testing
- Low-Dose REGN4461, High-dose REGN4461
- Where
- 8 sites in United States, Peru and 2 more
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Hyperlipidemia
A Mobile Personal Health Record for Behavioral Health Homes
Poor quality of medical care is a major contributor to excess medical morbidity and premature mortality in persons with serious mental illnesses (SMI).
- Conditions
- Hypertension, Hyperlipidemia, Diabetes
- Trial name
- mPHR (NCT01890226)
- Testing
- Mobile Personal Health Record App.
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Emory University
Hypercholesterolemia
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
This study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high cardiovascular risk patients with…
- Trial name
- NCT01154036
- Testing
- ezetimibe 10 mg, atorvastatin, Comparator: rosuvastatin
- Volunteers
- 1,547 people
- Sponsor
- Organon and Co
Dyslipidemias, Hypercholesterolemia
Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols
Hypercholesterolemia is an important risk factor for cardiovascular disease, asociated primarily with high plasma levels of LDL lipoprotein, which in turn depend on the endogenous hepatic synthesis of cholesterol and its…
- Trial name
- ACTICOL (NCT02644109)
- Testing
- Phytosterol
- Where
- 2 sites in Chile
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Chile
Dyslipidemia
MK0524A Bioequivalence Study (0524A-059)
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.
- Trial name
- NCT00944645
- Testing
- niacin (+) laropiprant (Source 1), Comparator: niacin (+) laropiprant (Source 2)
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemias
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.
- Trial name
- NCT02719028
- Testing
- Antroquinonol
- Where
- 6 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Golden Biotechnology Corporation
Cardiovascular Diseases, Heart Diseases
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia
- Trial name
- HeartPositive (NCT00246376)
- Testing
- Diet, Exercise, Niacin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Baylor College of Medicine
Cardiovascular Diseases, Hypercholesterolemia
Vascular Lifestyle-Intervention and Screening in Pharmacy
The overall goal of the present project is to contribute to new knowledge about the effect of a low threshold population screening system for cardiovascular risk factors in Norway.
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Dyslipidemia, Hypertensive Disease
- Trial name
- VISA (NCT02223793)
- Testing
- Information on high risk factor levels and lifestyle advice, No information on high risk factor levels but lifestyle advice, No information on high risk factor levels, nor lifestyle advice
- Where
- Norway
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- University of Oslo
Severe Hypertriglyceridemia
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
This is a randomized, open-label crossover study. The primary objective of this study is to compare the relative bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and the…
- Trial name
- ECLIPSEIV (NCT02189252)
- Testing
- Epanova, Lovaza
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Homozygous Familial Hypercholesterolemia
Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
Identify new or novel genes which may impact on cholesterol level, and establish the relationship between those gene mutations with atherosclerosis, as well as responses to lipid-lowering drugs.
- Trial name
- NCT01878604
- Testing
- Gene analysis, Historical data of lipid-lowering drug administration, Historical data of plasma lipids, xanthoma changes
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Central South University
Spinal Cord Injury
Testosterone and Long Pulse Stimulation After SCI
Denervation following spinal cord injury (SCI) limits beneficial application of neuromuscular electrical stimulation (NMES). SCI with denervation results in extensive muscle atrophy that is accompanied with several…
- Trial name
- NCT03345576
- Testing
- Testosterone and LPWS, Testosterone and standard NMES
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01644175
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 76 sites in United States
- Volunteers
- 316 people
- Sponsor
- Sanofi
Aging, Obesity
Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
A. HYPOTHESES: In older men low testosterone levels, abdominal obesity and elevated fasting insulin who are at risk for the cardiovascular complications such as heart attack and stroke. 1.
- Conditions
- Aging, Obesity, Insulin Resistance, Hypogonadism
- Trial name
- NCT00365794
- Testing
- Topical testosterone gel 10 g/day
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Obesity
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of…
- Trial name
- NCT00395135
- Testing
- Lorcaserin 10 mg BID
- Where
- United States
- Volunteers
- 3,182 people
- Sponsor
- Eisai Inc.
Diabetes Mellitus
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and…
- Trial name
- PLANET 1 (NCT00296374)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 116 sites in United States, Argentina and 9 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Gout, Hyperuricemia
The Diet Gout Trial
Unhealthy diet has long been associated with high uric acid levels and gout. The DASH diet may lower uric acid levels. This study will examine the effects of the DASH diet on uric acid in adults with a history of gout.
- Trial name
- DIGO (NCT03569020)
- Testing
- Subsidy for food purchases and dietitian education
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Cerebrotendinous Xanthomatosis (CTX)
Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a…
- Trial name
- NCT02638220
- Where
- 44 sites in United States
- Volunteers
- 442 people
- Sponsor
- Travere Therapeutics, Inc.
Dyslipidemias, Hyperlipidemias
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered…
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Trial name
- NCT04516291
- Testing
- Vupanorsen
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Pfizer